Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Hypertrophic cardiomyopathy secondary prevention

Introduction

Overview

Overview

Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening. Once HCM has been identified in a family, immediate testing of all family members will help to identify those at risk. Both imaging and genetic testing might be helpful. Athletes and military commanders (this in danger group barely discussed in the literature) are particularly in danger and it is recommended to undergo screening for HCM.

Secondary Prevention

Secondary Prevention

Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening by means of:[1][2][3][4][5][6][7].

  • Echocardiography
  • MRI
  • Genetic testing

Athletes and military commanders (this in danger group barely discussed in the literature) are particularly in danger and it is recommended to undergo screening for HCM.

ICD

Indications for implantable cardioverter-defibrillator (Secondary prevention)

  • Survivors of cardiac arrest
  • Sustained spontaneous ventricular arrhythmia
References

References

  1. ↑ Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33.
  2. ↑ Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.
  3. ↑ Maki S, Ikeda H, Muro A et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–8.
  4. ↑ Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.
  5. ↑ Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.
  6. ↑ Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE (2005). “Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome”. J. Am. Coll. Cardiol. 45 (8): 1340–5. doi:10.1016/j.jacc.2005.02.011. PMID 15837284. Unknown parameter |month= ignored (help)
  7. ↑ Pelliccia A, Fagard R, Bjørnstad HH; et al. (2005). “Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology”. Eur. Heart J. 26 (14): 1422–45. doi:10.1093/eurheartj/ehi325. PMID 15923204. Unknown parameter |month= ignored (help)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]